{
    "clinical_study": {
        "@rank": "1611", 
        "acronym": "PSM", 
        "arm_group": {
            "arm_group_label": "Observational study", 
            "description": "Patients diagnosed with PSM undergoing CRS with HIPEC."
        }, 
        "biospec_descr": {
            "textblock": "Metastatic tissue, blood specimens."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The aim of this study is to identify biomarkers of disease recurrence and prognosis to\n      optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic\n      intraperitoneal chemotherapy (HIPEC), and through animal models to explore different\n      treatment strategies for peritoneal surface malignancies (PSM)."
        }, 
        "brief_title": "Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies", 
        "completion_date": {
            "#text": "January 2023", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pseudomyxoma Peritonei.", 
            "Colorectal Carcinoma.", 
            "Ovarian Carcinoma.", 
            "Mesothelioma."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Colorectal Neoplasms", 
                "Mesothelioma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial", 
                "Pseudomyxoma Peritonei"
            ]
        }, 
        "detailed_description": {
            "textblock": "The handling of patients with PSM involves multimodal and multidisciplinary treatment\n      strategies such as CRS, the removal of all macroscopically detectable tumor, and HIPEC,\n      instillation of heated chemotherapy in the abdominal cavity to remove residual cancer\n      disease. The treatment is challenging and complex and associated with significant morbidity.\n      Only patients with limited disease will benefit from the treatment, and better methods for\n      patient selection are needed. The project group has a unique opportunity to address key\n      questions because of acquired experience, an exceptional biobank and institutional database\n      and novel animal models established at the Norwegian Radium Hospital."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age > 18 years\n\n          -  confirmed diagnosis of  peritoneal surface malignancy\n\n          -  candidate for CRS-HIPEC\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  none\n\n        Approximately 80 patients per year will be eligible for inclusion, as this is the number\n        of patients that annually receive surgical treatment for PSM."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients with PSM that are referred to Oslo University Hospital and are candidates for\n        CRS with HIPEC may be included in the study."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073500", 
            "org_study_id": "PSM_250913"
        }, 
        "intervention": {
            "arm_group_label": "Observational study", 
            "description": "Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.\nHIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.", 
            "intervention_name": "Observational study.", 
            "intervention_type": "Other", 
            "other_name": "Observational study. Laboratory biomarker analysis."
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peritoneal carcinomatosis", 
            "Peritoneal surface malignancy", 
            "Cytoreductive surgery", 
            "Hyperthermic intraperitoneal chemotherapy", 
            "CRS", 
            "HIPEC", 
            "Prognostic biomarker", 
            "Predictive biomarker"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "Kjersti.Flatmark@rr-research.no", 
                "last_name": "Kjersti Flatmark, MD PhD", 
                "phone": "+47 22 78 18 73"
            }, 
            "contact_backup": {
                "email": "atj@ous-hf.no", 
                "last_name": "Annette Torgunrud Kristensen, PhD", 
                "phone": "+47 22 78 23 12"
            }, 
            "facility": {
                "address": {
                    "city": "Oslo", 
                    "country": "Norway"
                }, 
                "name": "The Norwegian Radium Hospital"
            }, 
            "investigator": {
                "last_name": "Kjersti Flatmark, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.", 
        "overall_contact": {
            "email": "Kjersti.Flatmark@rr-research.no", 
            "last_name": "Kjersti Flatmark, MD PhD", 
            "phone": "+47 22 78 18 73"
        }, 
        "overall_contact_backup": {
            "email": "atj@ous-hf.no", 
            "last_name": "Annette Torgunrud Kristensen, PhD", 
            "phone": "+47 22 78 23 12"
        }, 
        "overall_official": {
            "affiliation": "Oslo University Hospital", 
            "last_name": "Kjersti Flatmark, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Norway: Regional Ethics Commitee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073500"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Oslo University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "The Research Council of Norway", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Oslo University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "April 2014"
    }
}